Summary: A landmark neuroregenerative study overturns a long-held assumption by showing that damage to the connections between the human brain and spinal cord—once thought irreversible—can be reversed. The researchers used patient-derived three-dimensional stem cell organoids grown in the lab for over a year to recreate human corticospinal development and to test strategies that restore axon growth.
Using these human “mini-brains” and spinal tissue models, the team pinpointed a precise genetic program that acts as a developmental maturity switch, shutting down axon regrowth around the mid-trimester of pregnancy. Crucially, they demonstrate that a licensed hormone drug, lynestrenol, can interfere with this program and reactivate axon regeneration, opening a potential therapeutic avenue for paralysis, motor neuron disease, and multiple sclerosis.
Key Facts
- The paralysis block identified: During embryonic and fetal development, neurons build long axons—nerve-fiber “cables” that transmit movement commands from the brain to spinal circuits and muscles. Clinical practice long assumed that central nervous system (CNS) neurons permanently lose this growth capacity as they mature, which explains why spinal injuries and many neurological diseases typically cause lasting disability.
- The living muscle circuit: Building on earlier cortical organoid work, Cambridge researchers cultivated separate brain and spinal cord organoids in the same dish. Over time, axons grew across the gap to form functioning, three-dimensional circuits that evoked contractions in small muscle clusters attached to the system.
- The day 150 maturity shift: By maintaining the model for more than a year, the team identified a discrete developmental window when regenerative capacity declines. Up to around day 150—corresponding to the human mid-trimester—axons regrew readily after injury. After day 150, as neurons matured and formed synaptic connections, there was a sharp, persistent decrease in their ability to regenerate.
- Toggling the genetic switch: Single-cell gene expression analysis revealed an integrated transcriptional network that functions as a switch to restrict axon growth during maturation. Biochemical blockade of key regulators within this network reverted mature neurons toward an embryonic-like growth state and reinstated axon elongation.
- Chemical intervention with lynestrenol: Screening a large compound database for agents that influence the identified gene network, the researchers selected lynestrenol, a hormone currently licensed for menstrual disorders and contraception. In damaged, mature human neuron models, lynestrenol significantly increased axon regrowth.
- Bridging the animal model gap: Much nerve-regeneration knowledge comes from rodent studies, but rodent neurons differ from human neurons. Human organoid-based systems provide a closer approximation of patient biology and help reduce reliance on animal models while advancing clinically relevant insights.
Source: University of Cambridge
Cambridge scientists have built miniature circuits in vitro that model how the brain and spinal cord connect to produce movement, and used this system to show that previously irreversible damage to these connections can be reversed.
During human development, neurons extend axons that connect brain regions with spinal circuits and muscles. Axons are the long projections that carry signals required for coordinated movement. At a certain point in development, the central nervous system’s capacity for axon elongation diminishes, which helps explain why injuries to the brain or spinal cord often produce permanent deficits such as paralysis or loss of hand function. Similar limitations in regeneration contribute to progression in disorders like motor neuron disease and multiple sclerosis.
In 2021, Dr András Lakatos and colleagues at the University of Cambridge developed cortical organoids from patient-derived stem cells—three-dimensional, pea-sized models resembling parts of the human cerebral cortex. Those organoids previously helped reveal molecular defects in motor neuron disease and suggested intervention strategies. The new study extends this approach by creating a connected corticospinal organoid model that pairs cortical and spinal slices while keeping them spatially separated, enabling targeted observation of cortical projection neurons and their axons.
When the researchers cultured separate brain and spinal tissue organoids in the same environment, cortical axons grew across the intervening space and formed functional connections with spinal tissue. These connections were capable of driving contractions in attached miniature muscle clusters, demonstrating physiological relevance of the platform.
Maintaining the model over extended time revealed a reproducible timeline: axon regrowth after injury remained robust up to roughly day 150, but declined sharply thereafter as neurons matured and formed synapses. George Gibbons, the study’s first author, explains that immature neurons regrew long axons after injury, whereas more mature neurons showed a pronounced loss of regenerative ability—indicating that the loss of plasticity is encoded in the developmental program of human CNS neurons.
Single-cell transcriptomics and computational analyses uncovered a maturation-associated transcriptional shift that suppresses axon growth. By targeting the regulators of this shift, the investigators reversed the decline and restored post-injury axon elongation. Their drug-screening efforts highlighted lynestrenol as a repurposable compound that acts on components of the identified gene network and promotes axon regrowth in the mature human neuron models.
The authors emphasize that additional barriers to repair—such as scarring and inflammation at injury sites—also influence recovery. Nevertheless, demonstrating that intrinsic neuronal programs can be reactivated in human cells is a crucial step. Immature axons can traverse non-permissive environments, suggesting that combining cell-intrinsic reactivation with strategies to reduce extracellular barriers could improve clinical outcomes.
Senior author Dr András Lakatos notes that while lynestrenol itself may not become the definitive therapy for spinal-cord repair, it proves the principle that human neurons can be pharmacologically pushed back into a growth-competent state. The next challenge is to show that newly regrown axons can re-establish accurate, functionally appropriate connections in the intact nervous system—a necessary requirement for restoring meaningful movement.
Organoid platforms offer a human-specific window into development, disease, and repair strategies that animal models cannot fully replicate. These models are increasingly used across disciplines—from modeling early pregnancy and intestinal disease to testing regenerative approaches—because they more closely reflect human cellular behavior and reduce dependence on rodent-based inference.
Funding: The study was supported by UK Research and Innovation, the Medical Research Council, and Spinal Research.
Key Questions Answered:
A: The research indicates a built-in developmental shutdown within the human central nervous system. During early development, axons extend readily, but around day 150 of gestation a transcriptional program engages that restricts axon growth as neurons mature. That intrinsic change leaves adult CNS neurons genetically limited in their ability to regrow long axons after injury.
A: After mapping the gene network that suppresses axon growth, researchers screened for compounds that modify that network. They identified lynestrenol, which when applied to damaged mature human neurons in the organoid system, altered the maturation-associated transcriptional program and restored axon elongation, effectively reactivating a growth-competent state.
A: This work is an important proof of concept but not a clinical cure. Lynestrenol demonstrates that human axon regeneration can be reawakened after the developmental block, but further research is needed to confirm that regrown axons can reconnect accurately within the complex anatomy of the nervous system and deliver functional recovery in patients.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The full journal paper was reviewed.
- Additional explanatory context was provided by editorial staff.
About this neurology and spinal cord injury research news
Author: Fred Lewsey
Source: University of Cambridge
Contact: Fred Lewsey – University of Cambridge
Image: The image is credited to Dr András Lakatos
Original Research: Open access. “A human corticospinal organoid-slice connectoid model informs enhancer strategies for post-injury axon regrowth” by George M. Gibbons et al., published in Cell Reports. DOI:10.1016/j.celrep.2026.117399
Abstract
A human corticospinal organoid-slice connectoid model informs enhancer strategies for post-injury axon regrowth
Axon elongation in the mammalian central nervous system (CNS) declines during development, limiting regenerative capacity after birth. Intrinsic regulators of this process are promising repair targets, as immature axons can regrow in tissues otherwise not conducive to regeneration. Yet the precise timing and mechanisms underlying the cessation of axon growth in the human CNS remain unresolved.
Here, we developed a three-dimensional human corticospinal motor organoid-slice connectoid platform mimicking the developmental axon elongation program and its subsequent restriction through maturation.
Cortical and spinal slices establish functional connections while remaining spatially segregated, enabling cortical cell-type-specific observations without direct confounding effects by spinal cells. Using single-cell transcriptomics, computational analyses, axon regrowth assays, and live imaging, we identified transcriptional alterations contributing to decreased axon growth in maturing human cortical projection neurons.
We further demonstrate that this decline can be reversed using compounds and repurposable drugs targeting a maturation-associated transcriptional shift, promoting post-injury axon repair.